Total Reports
11
Low report volume
Dog /
Breed profile · FDA CVM July 2026 extract
New Guinea Singing Dog adverse-event record
Adverse-event filings for New Guinea Singing Dog (Dog) in the FDA Center for Veterinary Medicine openFDA extract. Browse dog breeds, reactions, and outcomes below.
- #430 of 510
- by report volume (all breeds)
- 11
- FDA CVM reports on file
- 0.0%
- death-coded share of reports
- 2
- Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
How the 11 reports break down
By recorded gender -- every report on file for New Guinea Singing Dog, no filtering.
Annual report volume
Data updated September 2026
The verdict
According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, New Guinea Singing Dog ranks #427 of 510 by total reports (11). Death-coded-share rank requires at least 50 reports. National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).
- 93,675
- Retriever - Labrador reports (#1)
- 99.0%
- Atlantic Salmon (Salmo salar) death share (#1)
- #427
- This breed, reports of 510
Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.
Release-over-release change
What changed in the latest FDA data snapshot
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. New Guinea Singing Dog has 11 reports now versus 11 in that prior snapshot: 0 the same number of (0.0%).
- Report change
- +0
- Death-coded reports
- +0
- Death-coded share
- +0.0 pts
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to New Guinea Singing Dog changesDeaths Reported
0
of 11 reports
Death-coded share of reports
0.0%
0.0% death-coded
Avg Age at Report
5.0 yr
no age data
Death-Coded Outcome Share
New Guinea Singing Dog death-coded reports 0.0%
Cross-breed median
0.0% of 11 new guinea singing dog reports involved a death outcome.
How to read this number
Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
Top Reported Reactions
Lethargy (see also Central nervous system depression in 'Neurological') 2
Lack of efficacy (endoparasite) - heartworm 2
INEFFECTIVE, ATOPY CONTROL 1
Inappropriate schedule of drug administration 1
Skin lesion NOS 1
Most Referenced Drugs
Moxidectin 5
Oclacitinib Maleate 2
Butorphanol 2
Anti-Il31 Mab Mcs Lot #1283563 1
Canine Parvovirus Strain Nl-35-D, P.35-D, 8-2-80;Canine Parainfluenza Virus, Str 1
Outcome Breakdown
Recovered/Normal
5 (45.5%)
Ongoing
4 (36.4%)
Outcome Unknown
2 (18.2%)
Gender Distribution
Unknown 11 (100.0%)
Reports by Year
| Year | Reports | Trend |
|---|---|---|
| 2018 | 1 | |
| 2019 | 3 | |
| 2020 | 3 | |
| 2021 | 4 | |
New Guinea Singing Dog: low death-coded share in the FDA CVM extract
Signature read: 11 reports place New Guinea Singing Dog in the lower third of breed filing volume (#430 of 510). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, New Guinea Singing Dog sits at #430 of 510 by report volume among all breeds and #270 of 298 among dog breeds, with 11 reports and 0 (0.0%) death-coded. Mean age at report: 5.0 years.
Top reported signs: Lethargy (see also Central nervous system depression in 'Neurological') (2), Lack of efficacy (endoparasite) - heartworm (2), INEFFECTIVE, ATOPY CONTROL (1). Most-referenced drug: Moxidectin (5 reports), followed by Oclacitinib Maleate (2) and Butorphanol (2).
Outcome coding on 11 status-recorded reports is dominated by Recovered/Normal (45.5%). Annual submissions ranged 1-2,021 across 4 years on file.
Dog Breeds With a Similar Report Volume
Showing 6 of 297 dog breeds in our dataset, ranked by closest report volume.
What to do with this dog
- Read how death-coded share differs from a mortality rate before drawing conclusions. Breed-specific risks guide
- Browse every dog breed we track for comparison. All dog breeds
A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.
Frequently Asked Questions
How many FDA adverse event reports involve New Guinea Singing Dog? ▼
There are 11 adverse event reports involving New Guinea Singing Dog in the FDA database, of which 0 were death-coded (0.0% of those reports). That is a share of REPORTED events, not a mortality rate for the breed: adverse events reach the FDA when something goes wrong, so the denominator is reports, never the population of animals. According to the same FDA CVM extract, New Guinea Singing Dog ranks #430 of 510 by report volume among all breeds PlainBreed indexes (#270 of 298 among dog breeds).
Where does New Guinea Singing Dog sit among other breeds in PlainBreed's corpus? ▼
According to FDA CVM report volume, New Guinea Singing Dog is #430 of 510 breeds indexed on PlainBreed (same ordering as the most-reported-breeds ranking). Inside Dog, it is #270 of 298. It has fewer than 50 reports, so it is outside the death-rate ranking cohort (≥50 reports). These are placement ranks in the reporting corpus, not clinical risk scores.
What are the most common adverse reactions reported for New Guinea Singing Dog? ▼
The most commonly reported adverse reactions for New Guinea Singing Dog are Lethargy (see also Central nervous system depression in 'Neurological') (2 reports), Lack of efficacy (endoparasite) - heartworm (2 reports), INEFFECTIVE, ATOPY CONTROL (1 reports), Inappropriate schedule of drug administration (1 reports), Skin lesion NOS (1 reports).
What drugs are most frequently associated with New Guinea Singing Dog adverse events? ▼
The drugs most frequently referenced in New Guinea Singing Dog adverse event reports are Moxidectin (5 reports), Oclacitinib Maleate (2 reports), Butorphanol (2 reports), Anti-Il31 Mab Mcs Lot #1283563 (1 reports), Canine Parvovirus Strain Nl-35-D, P.35-D, 8-2-80;Canine Parainfluenza Virus, Str (1 reports).
What is the average age of New Guinea Singing Dog in adverse event reports? ▼
The average age of New Guinea Singing Dog at the time of adverse event reports is 5.0 years.
Compare a breed's report volume against how common the breed is before drawing conclusions. See our methodology for how the death-coded share and rankings are computed, or read breed-specific reporting patterns and FDA CVM reporting.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
openFDA Animal & Veterinary Adverse Events (FDA CVM) for New Guinea Singing Dog (Dog), extract as of July 2026 extract. 11 reports · 0 death-coded (0.0% of reports, not a mortality rate) · #430 of 510 by volume.
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →